316 related articles for article (PubMed ID: 24958881)
21. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
Younis S; Faber BW; Kocken CHM; Remarque EJ
BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
[TBL] [Abstract][Full Text] [Related]
22. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion.
Kocken CH; Withers-Martinez C; Dubbeld MA; van der Wel A; Hackett F; Valderrama A; Blackman MJ; Thomas AW
Infect Immun; 2002 Aug; 70(8):4471-6. PubMed ID: 12117958
[TBL] [Abstract][Full Text] [Related]
23. Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.
Laurens MB; Kouriba B; Bergmann-Leitner E; Angov E; Coulibaly D; Diarra I; Daou M; Niangaly A; Blackwelder WC; Wu Y; Cohen J; Ballou WR; Vekemans J; Lanar DE; Dutta S; Diggs C; Soisson L; Heppner DG; Doumbo OK; Plowe CV; Thera MA
PLoS One; 2017; 12(3):e0173294. PubMed ID: 28282396
[TBL] [Abstract][Full Text] [Related]
24. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.
Yoshida S; Nagumo H; Yokomine T; Araki H; Suzuki A; Matsuoka H
PLoS One; 2010 Oct; 5(10):e13727. PubMed ID: 21060850
[TBL] [Abstract][Full Text] [Related]
25. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
27. PfRON3 is an erythrocyte-binding protein and a potential blood-stage vaccine candidate antigen.
Zhao X; Chang Z; Tu Z; Yu S; Wei X; Zhou J; Lu H; Jiang N; Chen Q
Malar J; 2014 Dec; 13():490. PubMed ID: 25495792
[TBL] [Abstract][Full Text] [Related]
28. Defining species-specific and conserved interactions of apical membrane protein 1 during erythrocyte invasion in malaria to inform multi-species vaccines.
Drew DR; Wilson DW; Weiss GE; Yeoh LM; G Henshall I; Crabb BS; Dutta S; Gilson PR; Beeson JG
Cell Mol Life Sci; 2023 Feb; 80(3):74. PubMed ID: 36847896
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
30. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.
Drew DR; Hodder AN; Wilson DW; Foley M; Mueller I; Siba PM; Dent AE; Cowman AF; Beeson JG
PLoS One; 2012; 7(12):e51023. PubMed ID: 23227229
[TBL] [Abstract][Full Text] [Related]
31. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Elias SC; Choudhary P; de Cassan SC; Biswas S; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Hodgson SH; Duncan CJ; Hill AV; Draper SJ
Immunology; 2014 Apr; 141(4):628-44. PubMed ID: 24303947
[TBL] [Abstract][Full Text] [Related]
32. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model.
Dutta S; Sullivan JS; Grady KK; Haynes JD; Komisar J; Batchelor AH; Soisson L; Diggs CL; Heppner DG; Lanar DE; Collins WE; Barnwell JW
PLoS One; 2009 Dec; 4(12):e8138. PubMed ID: 19997632
[TBL] [Abstract][Full Text] [Related]
33. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
Shi Q; Lynch MM; Romero M; Burns JM
Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
[TBL] [Abstract][Full Text] [Related]
34. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
Miura K; Zhou H; Diouf A; Moretz SE; Fay MP; Miller LH; Martin LB; Pierce MA; Ellis RD; Mullen GE; Long CA
Clin Vaccine Immunol; 2009 Jul; 16(7):963-8. PubMed ID: 19439523
[TBL] [Abstract][Full Text] [Related]
35. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
[TBL] [Abstract][Full Text] [Related]
36. Juxtamembrane shedding of Plasmodium falciparum AMA1 is sequence independent and essential, and helps evade invasion-inhibitory antibodies.
Olivieri A; Collins CR; Hackett F; Withers-Martinez C; Marshall J; Flynn HR; Skehel JM; Blackman MJ
PLoS Pathog; 2011 Dec; 7(12):e1002448. PubMed ID: 22194692
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
[TBL] [Abstract][Full Text] [Related]
38. Rhoptry neck protein RON2 forms a complex with microneme protein AMA1 in Plasmodium falciparum merozoites.
Cao J; Kaneko O; Thongkukiatkul A; Tachibana M; Otsuki H; Gao Q; Tsuboi T; Torii M
Parasitol Int; 2009 Mar; 58(1):29-35. PubMed ID: 18952195
[TBL] [Abstract][Full Text] [Related]
39. Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05-09 antigen could be a malaria vaccine candidate.
Dinga JN; Gamua SD; Ghogomu SM; Titanji VPK
Parasite Immunol; 2018 Mar; 40(3):. PubMed ID: 29284177
[TBL] [Abstract][Full Text] [Related]
40. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.
Narum DL; Ogun SA; Thomas AW; Holder AA
Infect Immun; 2000 May; 68(5):2899-906. PubMed ID: 10768987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
